Tarbox Family Office’s Ultragenyx Pharmaceutical RARE Stock Holding History

Tarbox Family Office’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-17	Closed	-$1K	–	776
2022 Q1	$1K	Hold	17	–	–	﹤0.01%	1002
2021 Q4	$1K	Hold	17	–	–	﹤0.01%	1047
2021 Q3	$2K	Hold	17	–	–	﹤0.01%	959
2021 Q2	$2K	Hold	17	–	–	﹤0.01%	968
2021 Q1	$2K	Hold	17	–	–	﹤0.01%	922
2020 Q4	$2K	Hold	17	–	–	﹤0.01%	881
2020 Q3	$1K	Hold	17	–	–	﹤0.01%	1039
2020 Q2	$1K	Hold	17	–	–	﹤0.01%	1036
2020 Q1	$1K	Buy	+17	New	+$883	﹤0.01%	961

Other funds holding RARE

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Tarbox Family Office's RARE Position: Q2 2022 in Review

Tarbox Family Office sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2022, closing a stake of 17 shares — an estimated $1K sold.

Tarbox Family Office first reported a position in RARE in Q1 2020 and held it in 9 quarters. The position peaked at $2K in Q3 2021. 224 funds tracked by Wall St. Rank hold RARE as of Q2 2022.

Tarbox Family Office reported no remaining Ultragenyx Pharmaceutical position as of Q2 2022 after selling out during the quarter.
Tarbox Family Office sold 17 Ultragenyx Pharmaceutical shares in Q2 2022, an estimated $1K.
Tarbox Family Office first reported a position in Ultragenyx Pharmaceutical in Q1 2020 and held it in 9 quarters.
Tarbox Family Office's Ultragenyx Pharmaceutical position peaked at $2K in Q3 2021.
224 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2022.

Based on Tarbox Family Office's 13F filing for Q2 2022, filed 19 Jul 2022.